OM1 focuses on enhancing patient outcomes in healthcare through data analytics and artificial intelligence. The company specializes in chronic diseases, utilizing real-world data (RWD) collected from sources like electronic health records and insurance claims. This data is analyzed to produce real-world evidence (RWE), which informs how treatments work in everyday settings. One of OM1's main products is Aspen, an automated platform that predicts patient outcomes and aids healthcare decisions. Unlike competitors, OM1 emphasizes the use of AI to identify patients with specific conditions and forecast treatment results, allowing for more tailored care. The goal of OM1 is to provide actionable insights that improve patient care and support the development of new treatments.

Glikvest

D1 Capital Partners

Breyer Capital

Scale Venture Partners

General Catalyst

7wire Ventures

General Catalyst Partners

Kaiser Permanente

Polaris Partners

Wanxiang Healthcare Investments

Data & Analytics

AI & Machine Learning

Healthcare

What You Should Know:–  OM1, the leader in real-world insights synthesis and evidence generation for life sciences supporting population and personalized data insights, evidence generation through advanced validated AI platforms, big deep clinical data, registries, and globally recognized thought leadership today announced the new release of its Alzheimer’s disease PremiOM dataset.– OM1 combines multiple real-world data sources – including specialists’ electronic medical records (EMR), medical and pharmacy claims, social determinants of health (SDoH), and mental health assessments – with medical language processing and advanced AI capabilities to generate deep clinical insights for patients with Alzheimer’s disease.OM1: Advancing Alzheimer’s Research with Cutting-Edge Healthcare InnovationOM1 is at the forefront of healthcare innovation, leveraging insights-driven technology and data to revolutionize personalized medicine, evidence generation, and real-world evidence (RWE) research. The company utilizes next-generation AI platforms, regulatory-grade deep longitudinal data, and globally recognized thought leadership to achieve these goals.“We know that the pathogenesis of Alzheimer’s can begin decades before clinical symptoms emerge. And, while exciting, the new disease-modifying therapies entering the market for the first time only have a modest impact on a person’s disease journey if they are already in advanced cognitive decline,” said Carl Marci, MD, Chief Clinical Officer and Managing Director of Mental Health and Neuroscience at OM1. “This, combined with the fact there is no cure, makes early detection and intervention to boost neuro-resiliency in patients even more crucial.”Led by a diverse team of scientists, engineers, researchers, and clinicians with over 30 years of experience in real-world data (RWD) and RWE, OM1 boasts a Real-World Data Cloud encompassing over one million patients. This patient data network advances research by:– Facilitating clinical trial recruitment– Uncovering prescriber trends– Modeling health economics and clinical outcomesIn addition to standard claims data, the dataset includes enriched clinical notes from over 17,000 patients within its national network of specialists treating Alzheimer’s patients. This comprehensive dataset provides deeper insights into patient journeys, enabling earlier intervention.Alzheimer’s disease, a progressive and degenerative brain disorder, impacts memory and other essential mental functions, ultimately affecting an individual’s physical, social, and financial health

Om1 Supporting Alzheimer’S Research And Care W/Expanded Dataset

OM1 earns Frost & Sullivan's 2024 North American New Product Innovation Award for transforming real-world evidence analytics solutions industry with its pioneering ai-powered platforms.

OM1 Earns Frost & Sullivan's 2024 North American New Product Innovation Award for Transforming Real-world Evidence Analytics Solutions Industry with Its Pioneering AI-powered Platforms

What You Should Know:–              OM1 introduces three new products: OM1 Orion, OM1 Lyra, and OM1 Polaris powered by PhenOMTM – an artificial intelligence-powered digital phenotyping platform for personalized medicine and clinical research.–              OM1 is the leader in providing Real-World Evidence (RWE) insights from bench to bedside, leveraging advanced predictive and generative AI platforms coupled with deep clinical data to empower healthcare stakeholders.Revolutionizing Healthcare with AI-Powered Solutions: OM1 PhenOM’s Impact on Patient Care and ResearchIn today’s healthcare landscape, disparate data sources create critical knowledge gaps from research and development to clinical decision-making. OM1 PhenOM stands out as a leader in innovative AI-powered solutions, addressing these challenges by providing insights that empower healthcare providers (HCPs) at the point of care, bridging gaps in patient journeys, and facilitating research and treatment for hard-to-find patient populations.PhenOM, launched last year, leverages OM1’s high-quality data cloud, comprising billions of data points from over 340 million patients. This platform improves individual care and population health by offering distinct product lines that integrate next-gen AI technology and clinically robust real-world data. Here’s how PhenOM tackles key pain points across the healthcare ecosystem:1. OM1 Orion: This solution caters to pharmaceutical decision-makers, offering a comprehensive view of the patient journey. By analyzing deep clinical data, OM1 Orion provides insights into disease progression and burden for specific patient sub-populations

Om1 Unveils Ai-Powered Phenotyping Platform For Personalized Medicine

For instance, OM1 launched its new AI-based platform in April 2023 to provide personalized information regarding clinical trials, use, risk, treatment, and diagnosis.

Global Biobanking Market Expected to Reach USD 101.1 Billion by 2033 - IMARC Group

OM1 appoints Shawn Bates as Chief Commercial Officer.

OM1 Appoints Shawn Bates as Chief Commercial Officer

Leading real-world data (RWD) and technology company OM1 has announced it is launching a research-grade dataset of curated RWD for Parkinson's disease (PD), expanding its Mental Health and Neuroscience RWD Network.

OM1 launches curated real-world dataset for Parkinson's disease to further neuroscience real-world evidence

OM1 appoints Catherine Richards as President.

OM1 Appoints Catherine Richards as President

HITRUST Enhances Cyber Threat Adaptive Engine Using Microsoft Azure OpenAI Service and Microsoft Defender Threat Intelligence
HITRUST, a leader in information security, risk, and compliance assurance, announced a comprehensive update to its Cyber Threat Adaptive engine to enable increased accuracy and timeliness of HITRUST CSF updates to address emerging cyber threats.

Health IT Business News - May 9, 2024

This is where the new Atlan anesthesia workstation family comes in, which Dräger has now launched in the United States.

Health IT Business News - October 5, 2023

OM1, a leading real-world data, AI, and technology company with a focus on chronic diseases, announced the launch of two new clinical datasets, Chronic Rhinosinusitis (CRS) and Asthma.

OM1 Launches Asthma and Chronic Rhinosinusitis Datasets to Expand Real-World Evidence in Respiratory and ENT

Healthcare technology for data analytics and outcomes

OM1

Healthcare technology for data analytics and outcomes

OM1

Healthcare technology for data analytics and outcomes

About

Simplify's Take

What believers are saying

What critics are saying

What makes OM1 unique

6 month growth

1 year growth

2 year growth

Recently Posted Jobs

OM1 is Hiring for 0 Jobs on Simplify!